About Aminomethyltransferase, mitochondrial
Aminomethyltransferase, mitochondrial (AMT) is a protein
from Homo sapiens identified by UniProt accession
P48728, 403 residues long.
MolForge cross-references it against 0 known binders and
172 disease associations.
Target properties
| Protein name | Aminomethyltransferase, mitochondrial |
| UniProt accession | P48728 |
| Gene | AMT |
| Organism | Homo sapiens |
| Length | 403 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (172)
Diseases linked to this target (Open Targets).
- glycine encephalopathy · score 0.78
- Neurodevelopmental delay · score 0.43
- neonatal glycine encephalopathy · score 0.37
- infantile glycine encephalopathy · score 0.37
- atypical glycine encephalopathy · score 0.37
- genetic disorder · score 0.34
- Red cell distribution width · score 0.12
- Seizure · score 0.12
- sex hormone-binding globulin measurement · score 0.10
- C-reactive protein measurement · score 0.09
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-P48728-F1 | alphafold | PREDICTED | 93.68 | — |
Amino-acid sequence (403 residues)
MQRAVSVVAR LGFRLQAFPP ALCRPLSCAQ EVLRRTPLYD FHLAHGGKMV AFAGWSLPVQ YRDSHTDSHL HTRQHCSLFD VSHMLQTKIL GSDRVKLMES LVVGDIAELR PNQGTLSLFT NEAGGILDDL IVTNTSEGHL YVVSNAGCWE KDLALMQDKV RELQNQGRDV GLEVLDNALL ALQGPTAAQV LQAGVADDLR KLPFMTSAVM EVFGVSGCRV TRCGYTGEDG VEISVPVAGA VHLATAILKN PEVKLAGLAA RDSLRLEAGL CLYGNDIDEH TTPVEGSLSW TLGKRRRAAM DFPGAKVIVP QLKGRVQRRR VGLMCEGAPM RAHSPILNME GTKIGTVTSG CPSPSLKKNV AMGYVPCEYS RPGTMLLVEV RRKQQMAVVS KMPFVPTNYY TLK
Explore Aminomethyltransferase, mitochondrial with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets